Literature DB >> 16890597

Immunohistochemical expression of MYH protein can be used to identify patients with MYH-associated polyposis.

Carmela Di Gregorio1, Milo Frattini, Stefania Maffei, Giovanni Ponti, Lorena Losi, Monica Pedroni, Tiziana Venesio, Lucio Bertario, Liliana Varesco, Mauro Risio, Maurizio Ponz de Leon.   

Abstract

BACKGROUND & AIMS: MYH-associated polyposis is a recently described, autosomal-recessive disease characterized by multiple colorectal adenomas and cancer. There are only few immunohistochemical studies of the MYH protein. We investigated the expression pattern of the MYH protein to evaluate whether a immunohistochemical approach could be used in clinical practice to screen patients for germline mutations in the MYH gene.
METHODS: The expression of MYH, MSH2, MLH1, and MSH6 proteins was studied by immunohistochemistry in 20 samples (colorectal adenomas or cancer) from 18 patients with biallelic MYH mutation, in 11 samples from patients with germline adenomatous polyposis coli (APC) mutations, in 20 samples from patients with sporadic colorectal cancers, and in 10 samples from patients with normal colonic mucosa without malignancies.
RESULTS: In all cases the mismatch repair proteins were expressed normally. Nuclear and cytoplasmic immunoreactivity for the MYH protein were observed in normal colorectal mucosa, in sporadic colorectal carcinomas, and in adenomas and carcinomas from patients carrying APC germline mutations. Adenomas and carcinomas from patients with MYH biallelic mutation showed a different pattern of expression: a strong granular cytoplasmic staining was observed without any nuclear expression. The same immunophenotype was observed in the surrounding normal mucosa.
CONCLUSIONS: Patients with biallelic MYH mutations showed disappearance of staining from the nucleus, and segregation of immunoreactivity in the cytoplasm, both in neoplastic and surrounding healthy mucosa. Because this pattern of expression seems to be specific for biallelic mutations, it follows that immunohistochemistry might be used in clinical practice to screen patients at risk for MYH-associated polyposis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16890597     DOI: 10.1053/j.gastro.2006.05.049

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  7 in total

1.  Immunohistochemistry is not an accurate first step towards the molecular diagnosis of MUTYH-associated polyposis.

Authors:  Rachel S van der Post; Carolien M Kets; Marjolijn J L Ligtenberg; Joannes H J M van Krieken; Nicoline Hoogerbrugge
Journal:  Virchows Arch       Date:  2008-11-25       Impact factor: 4.064

2.  Impaired suppressive activities of human MUTYH variant proteins against oxidative mutagenesis.

Authors:  Kazuya Shinmura; Masanori Goto; Hong Tao; Shun Matsuura; Tomonari Matsuda; Haruhiko Sugimura
Journal:  World J Gastroenterol       Date:  2012-12-21       Impact factor: 5.742

3.  Pathological features of colorectal carcinomas in MYH-associated polyposis.

Authors:  A M O'Shea; S P Cleary; M A Croitoru; H Kim; T Berk; N Monga; R H Riddell; A Pollett; S Gallinger
Journal:  Histopathology       Date:  2008-06-28       Impact factor: 5.087

Review 4.  Pathology of the hereditary colorectal carcinoma.

Authors:  Zoran Gatalica; Emina Torlakovic
Journal:  Fam Cancer       Date:  2007-06-13       Impact factor: 2.375

5.  Genetic testing for young-onset colorectal cancer: case report and evidence-based clinical guidelines.

Authors:  Yaolin Zhou; Lisa A Boardman; Robert C Miller
Journal:  Radiol Oncol       Date:  2010-03-18       Impact factor: 2.991

6.  MUTYH-associated polyposis (MAP), the syndrome implicating base excision repair in inherited predisposition to colorectal tumors.

Authors:  Tiziana Venesio; Antonella Balsamo; Vito G D'Agostino; Guglielmina N Ranzani
Journal:  Front Oncol       Date:  2012-08-02       Impact factor: 6.244

7.  Contribution of APC and MUTYH mutations to familial adenomatous polyposis susceptibility in Hungary.

Authors:  Janos Papp; Marietta Eva Kovacs; Zoltan Matrai; Enikő Orosz; Miklós Kásler; Anne-Lise Børresen-Dale; Edith Olah
Journal:  Fam Cancer       Date:  2016-01       Impact factor: 2.375

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.